Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q83400035)
Watch
English
Cardiovascular safety and diabetes drug development
scientific article published on 01 March 2011
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
title
Cardiovascular safety and diabetes drug development
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
author
Allison B Goldfine
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
Daniel J. Drucker
series ordinal
1
object named as
Daniel J Drucker
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
language of work or name
English
0 references
publication date
1 March 2011
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
volume
377
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
issue
9770
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
page(s)
977-979
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
cites work
Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Assessing the cardiovascular safety of diabetes therapies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962299-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(10)62299-4
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
PubMed ID
21316097
1 reference
stated in
Europe PubMed Central
PubMed ID
21316097
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21316097%20AND%20SRC:MED&resulttype=core&format=json
retrieved
22 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit